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To efficiently initiate immune responses to skin 
pathogens, migratory DCs capture antigens, 
undergo maturation, and enter lymphatic ves-
sels leading them into LNs (Banchereau and 
Steinman, 1998). Although the migration of 
skin DCs to LNs is critical for most vaccination 
procedures (Romani et al., 2010), the sequence 
of events regulating their mobilization has not 
been delineated fully.
DCs in the mammalian skin can be broadly 
divided into two populations: Langerhans cells 
(LCs) in the epidermis, and dermal DCs (DDCs) 
in the dermis (Merad et al., 2008; Bedoui et al., 
2009). Recent findings have used combinations 
of the markers CD103, CD207, and CD11b to 
further divide DDCs into subpopulations, each 
specializing in immune responses against dif-
ferent pathogens (Bedoui et al., 2009; Brewig 
et al., 2009).
For many years, LCs had been considered 
the major population of antigen-presenting 
cells to prime immune responses against skin 
antigens. More recently, the deeper and scarcer 
DDCs emerged as central players. They are the 
first cells to appear in draining LNs carrying 
antigen  from  the  skin  (Kamath  et  al.,  2002; 
Itano et al., 2003; Kissenpfennig et al., 2005), 
were found to be more motile than LCs in situ 
(Lindquist  et  al.,  2004;  Kissenpfennig  et  al., 
2005; Ng et al., 2008), and proved superior in 
priming certain immune responses (Helft et al., 
2010). The present study focuses on this key 
population of skin DCs.
Under inflammatory conditions, skin DCs, 
and first among them DDCs, are recruited to 
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Dendritic cells (DCs) must travel through lymphatics to carry skin antigens into lymph 
nodes. The processes controlling their mobilization and migration have not been completely 
delineated. We studied how DCs in live mice respond to skin inflammation, transmigrate 
through lymphatic endothelium, and propagate in initial lymphatics. At steady state, dermal 
DCs remain sessile along blood vessels. Inflammation mobilizes them, accelerating their 
interstitial motility 2.5-fold. CCR7-deficient BMDCs crawl as fast as wild-type DCs but  
less persistently. We observed discrete depositions of CCL21 complexed with collagen-IV  
on the basement membrane of initial lymphatics. Activated DCs move directionally toward 
lymphatics, contact CCL21 puncta, and migrate through portals into the lumen. CCR7-
deficient DCs arrive at lymphatics through random migration but fail to dock and trans-
migrate. Once inside vessels, wild-type DCs use lamellipodia to crawl along lymphatic 
endothelium and, sensing lymph flow, proceed downstream. DCs start drifting freely only in 
collecting lymphatics. These results demonstrate in vivo that the CCL21–CCR7 axis plays a 
dual role in DC mobilization: promoting both chemotaxis and arrest of DCs on lymphatic 
endothelium. Intralymphatic crawling, in which DCs combine active adhesion-based migra-
tion and directional cues from lymph flow, represents a new step in DC mobilization which 
may be amenable to regulation.
© 2011 Tal et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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buttons remain in position and act as hinges (Pflicke and Sixt, 
2009). How CCR7 signaling is incorporated into this com-
plex microanatomical setup remains unknown.
Unlike the entry of leukocytes into lymphatic capillaries, 
a process which is beginning to be unraveled, little is known 
about the mode of DC propagation inside these vessels. The 
simplest scenario suggests that DCs are passively swept along 
the lymph flow (Alvarez et al., 2008). This mode of transport 
would mimic the fast drift of tumor cells in tumor-draining 
lymphatics, which was observed in vivo by several groups 
(Dadiani et al., 2006; Hayashi et al., 2007), and could explain 
the presence of free-floating veiled DCs in lymph fluid har-
vested from afferent lymphatics (Kelly et al., 1978). It is yet 
unclear, though, whether the narrow cross section of initial 
lymphatics and the hydrodynamic forces that prevail inside 
them would support such motion. Notably, within inflamed 
venules, which, like initial lymphatics, are narrow and slow 
flowing, leukocytes use an elaborate array of chemokines and 
adhesion molecules to interact with the endothelium, crawl, 
and extravasate (Ley et al., 2007).
As initial lymphatics converge into collecting vessels, DCs 
would be expected to drift passively inside them. Secondary 
collecting lymphatics are sectioned into rhythmically con-
tracting lymphangions separated by valves. These structures 
actively pump lymph toward the draining LN (Swartz et al., 
2008) at velocities sufficient to carry cells (Dadiani et al., 
2006; Hayashi et al., 2007).
In recent years, multiphoton imaging in live animals has 
revealed  how  leukocytes  travel  in  lymphoid  tissues  and   
target organs (Germain et al., 2006). Researchers captured 
DCs  as  they  migrate  in  the  skin  (Lindquist  et  al.,  2004;   
Ng et al., 2008; Pflicke and Sixt, 2009; Sen et al., 2010) and 
in LNs (Lindquist et al., 2004; Miller et al., 2004) but have 
not applied this method to the question of DC propagation 
in lymphatics (Cavanagh and Weninger, 2008) and the role 
of specific chemokine receptors. In this paper, we aim to 
examine DCs in the skin of live mice and address the fol-
lowing questions: (a) whether DDCs occupy a defined niche 
in the skin and how they respond to skin inflammation;   
(b) what anatomical route DCs follow to access lymphatics   
and where along this route CCL21-CCR7 signaling regu-
lates DCs recruitment; and (c) how DCs propagate inside   
lymphatics  and  what  role  lymph  flow  plays  in  directing   
this migration.
RESULTS
To investigate how DCs migrate in the skin and mobilize, 
we modified a method for noninvasive imaging of the hind 
footpad in anesthetized mice (Zinselmeyer et al., 2008). We 
visualized  endogenously  fluorescent  DDCs  or  adoptively 
transferred BM-derived DCs (BMDCs), and their interaction 
with lymphatics (immunolabeled in vivo) using two-photon 
intravital microscopy.
Choosing the footpad allowed us to immobilize it under 
a chamber while maintaining normal blood flow, tissue oxy-
genation, and body temperature. Imaging this area has the   
the LNs en masse. This recruitment depends on a cascade of 
events that starts as keratinocytes and skin leukocytes recog-
nize microbial ligands using their pattern recognition recep-
tors, proceeds as they secrete inflammatory mediators such as 
leukotrienes, prostaglandins, and cytokines, and continues as 
lymphatic endothelial cells (LECs) release chemokines and 
DCs change their chemokine receptor profile (Randolph   
et al., 2005; Alvarez et al., 2008).
A pivotal chemokine receptor is CCR7, which is up-
regulated by migratory DCs and acts as a gatekeeper of their 
mobilization (Dieu et al., 1998; Saeki et al., 1999). As cor-
roborated in knockout mice, without engagement of CCR7 
DCs do not enter lymphatics and do not appear in LNs sev-
eral hours later (Förster et al., 1999; Martín-Fontecha et al., 
2003; Ohl et al., 2004). Complementary roles in DC mobili-
zation  have  been  suggested  for  CCR8-CCL1  (Qu  et  al., 
2004), CXCR4-CXCL12 (Kabashima et al., 2007), and S1P-
S1P1/3 signaling (Czeloth et al., 2005), but CCR7 seems to 
play the most central role.
The chemokines CCL21 (of which several variants exist) 
and CCL19 are the known ligands of CCR7. Based on work 
in mice deficient in these chemokines, CCL21 seems more 
important than CCL19 to mobilize skin DCs to LNs (Randolph 
et al., 2005; Britschgi et al., 2010). In contrast to CCL19, 
which is fully soluble, CCL21 has a heparan sulfate–binding 
domain which promotes its immobilization to various mem-
branal  and  matrix  proteins  (Patel  et  al.,  2001;  Kerjaschki   
et al., 2004; Yang et al., 2007).
The prevailing model has long been that CCR7+ DCs 
arrive at initial lymphatic vessels by migrating up a chemotac-
tic gradient of CCL19 and CCL21 secreted by the lymphatic 
vessels themselves (Saeki et al., 1999). This scenario, though, 
has not been demonstrated directly (Swartz et al., 2008).   
Recently, Schumann et al. (2010) demonstrated that DCs re-
quire both the immobilized form of CCL21 and the soluble 
form of CCL21, which they cleave off the immobilized form, 
to optimally spread and migrate in vitro. It was not revealed 
if this mechanism operates in the more complex in vivo   
milieu or would pertain to DC recruitment into lymphatics.
The microanatomical structure of initial lymphatics sup-
ports leukocyte entry. In the dermis, lymphatics form a flat 
network that runs beneath the epidermis. The lymphatic cap-
illaries are blind ended, have a flattened cross section, and are 
sheathed with a discontinuous basal membrane containing 
collagen IV (Pflicke and Sixt, 2009). The gaps in this mem-
brane, termed portals, serve as entry points for DCs to squeeze 
through and reach the lymphatic endothelium (Pflicke and 
Sixt, 2009). LECs display oak leaf morphology and adjoin 
each other through discrete cell junctions, termed buttons, 
interspersed by loose flaps (Baluk et al., 2007). The molecular 
composition of buttons resembles vascular adherens junctions 
and tight junctions, with an important component being vas-
cular endothelial cadherin (VE-cadherin), which maintains 
their structural integrity (Baluk et al., 2007). Based on exami-
nation of tissue explants, DCs are believed to enter lymphat-
ics by displacing the flaps into the lymphatic lumen while the JEM Vol. 208, No. 10 
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involved in DC migration (Gale et al., 
2007).  DDCs  in  this  layer  were 
amoeboid  in  their  morphology,   
far  sparser  than  LCs  (at  around   
110 cells/mm2), and heterogeneously 
distributed, with higher densities around blood vessels (Fig. 2 a). 
We are currently investigating the biological function of this 
unexpected  association  with  blood  vessels.  Whole-mount 
staining confirmed the presence of CD11c-EYFPhi MHC-II+ 
cells in this layer (Fig. S1). Hereafter, we focused on the dermal 
layer, dynamically imaging the interactions between DDCs 
and lymphatics.
Quiescent DCs are mobilized in response to inflammation
To begin assessing the response of DDCs to inflammation, 
we compared intact skin with skin injected with CFA 18–24 h 
earlier. We tracked the three-dimensional motion of the cells 
(Fig. 2, a–d; and Video 2) and quantified their velocity and 
arrest coefficient (which is the proportion of time that a cell 
is not crawling; Fig. 2, e and f). At steady state, DDCs exhib-
ited relatively little translational movement (0.78 µm/min on 
average).  Local  application  of  CFA  accelerated  DDCs   
almost 2.5-fold (Fig. 2 e), up to 2.06 µm/min (P < 0.001), 
and decreased their arrest coefficient from 0.80 to 0.61 (P < 
0.001; Fig. 2 f). Similarly motile CD11c-EYFP+ DCs were 
observed in injured skin (Video 3).
CCR7 signaling takes part in DC recruitment, participating 
in chemotaxis and, more critically, in DC docking  
to the lymphatic endothelium
After inflammation, CD11c-EYFP+ DDCs entered initial lym-
phatics and could be observed crawling inside them (Video 4). 
Nonetheless, cell numbers were low and we rarely captured 
events  of  trans-endothelial  migration.  To  observe  significant 
numbers of entry events, and to use genetically manipulated 
advantages of not requiring hair removal, less autofluores-
cence and photodamage in melanocytes and hair follicles, 
and simplified DC transfer.
DCs populations in the footpad skin
Using CD11c–enhanced (E) YFP mice, whose DCs, but not 
other cell types, express high levels of EYFP (Lindquist et al., 
2004), we could visualize the skin down to the s.c. space   
(located 120 µm deep), revealing all the epidermal and dermal 
layers (Fig. 1 and Video 1). Topical staining with the vital dye 
seminaphtharhodafluor (SNARF) revealed the stratum cor-
neum composed of cornified keratinocytes (Fig. 1, a and e). 
About 20 µm deeper into the epidermis resided flat highly 
branched EYFP+ cells, representing the LC population (Fig. 1, 
b and f). LCs were evenly spaced at a mean density of 1,000 
cells/mm2 and sent delicate dendrites from the cell soma. As 
expected, no blood or lymph vessels penetrated this layer. 
About 40 µm beneath the surface (Fig. 1 c), in the upper   
dermis, a basement membrane composed of collagen fibers 
was  clearly  visible  based  on  second  harmonic  generation. 
This layer was traversed by blood capillaries which we traced 
with quantum dot (QD) 655 nanoparticles. CD11c-EYFP+ 
DDCs first appeared at this depth, most of which adjoined 
blood vessels at a mean density of 60 cells/mm2. Scanning 
deeper into the dermis (65 µm below the surface), lym-
phatic vessels first appeared (Fig. 1, d and g). These were   
intertwined with blood vessels and exhibited a wider cross 
section and a simpler branched morphology. Lymphatics 
were stained by s.c. injection of antibody against lymphatic 
vessel hyaluronan receptor 1 (LYVE1), a surface marker not 
Figure 1.  Optical sectioning of the  
intact footpad skin from a live CD11c-
EYFP mouse. (a–d) Images representing 
extended focus views of subsequent layers. 
(a) The upper layer of the epidermis, at 0–20 µm   
in depth, consists of cornified keratinocytes 
stained topically with SNARF. (b) The epider-
mis, at 20–40 µm, contains CD11c-EYFP+ 
star-shaped LCs. (c) The upper dermis, at 
40–65 µm, contains collagen fibers, which 
generate a second harmonic signal, and 
blood vessels traced with QD655. (d) The 
deeper dermis, at 65–120 µm, contains 
CD11c-EYFP+ DDCs and lymphatics stained 
with anti-LYVE1 conjugated to Texas Red.  
(e–g) Three-dimensional reconstructions of 
all the above layers (e), epidermal LCs (f), and 
dermal lymphatics, DDCs and blood vessels 
shown from below (g). Images are represen-
tative of at least 15 paws of CD11c-EYFP+ 
mice examined.2144 DC migration toward and through lymphatics | Tal et al.
of their endothelium; and finally, (e) if 
it is required for crawling inside lym-
phatics, then they should accumulate 
on the luminal surface.
To  examine  these  possibilities, 
we s.c. injected the footpads of wild-
type host mice with fluorescently   
labeled BMDCs of either WT or 
CCR7/ origin. Suspensions con-
taining 3 × 106 BMDCs were in-
jected together with 50 ng LPS, and 
the dermis was imaged 18–24 h later. 
The  motion  of WT  DCs  toward 
lymphatics  showed  indications  of 
chemotaxis; because DCs were in-
jected  s.c.,  most  cells  approached 
lymphatics  from  below  (Video  5, 
right square) but when cells moved 
parallel to the surface, they could be 
tracked displaying linear motion toward the nearest lymphatic 
(Fig. 3 b; and Video 5, left). Within 24 h, 95% of WT cells in 
the imaged fields successfully transmigrated into the lymphatic 
lumen (Fig. 3 d and Video 6), whereas <5% of CCR7/  
DCs did so (Fig. 3 e and Video 6). Similar results were ob-
tained when both DC population were co-injected into the 
same host (Fig. 3 f and Video 7). Notably, about half of the 
CCR7/ cells were observed brushing against lymphatics 
but failing to arrest and enter them (Fig. 3 e, tracked cells; and 
Video 6). In the dermal interstitium, WT and CCR7/ DCs 
moved at similar velocities (6.37 vs. 7 µm/min, P = 0.29), but 
CCR7/ DCs followed more tortuous pathways as reflected 
in a lower persistence index (P = 0.006; Fig. 3, g and h). This 
implies that CCR7 signaling is not essential for DC chemo-
kinesis but participates in their chemotaxis. Correspondingly, 
CCR7/ DCs did not demonstrate linear motion toward 
the nearest lymphatics.
DCs in wild-type hosts, we proceeded to use adoptive transfer 
of BMDCs. These cells resemble the monocyte-derived DCs 
used in vaccination trials in cancer patients. Understanding 
the migration requirements of such cells is important because, 
when injected to the skin in clinical trials, typically <5% of 
them reach the draining LNs (De Vries et al., 2003).
DC mobilization is a multistep process that is tightly con-
trolled by CCR7 signaling. We set out to determine at what 
stages of DC mobilization CCR7 acts as a gatekeeper. We rea-
soned that: (a) If CCR7 signaling is required for DC chemokine-
sis, then CCR7/ DCs should exhibit reduced motility in the 
dermis; (b) if it is essential to chemoattract DCs, then CCR7/ 
DCs should not reach the lymphatics vessels; (c) if it is required 
for adherence to lymphatic endothelium, then they would reach 
the lymphatics but ignore them, continuing to migrate in the 
dermis; (d) if it is required for trans-endothelial migration, then 
DCs would accumulate outside lymphatics on the basal surface   
Figure 2.  Inflammation of the footpad 
accelerates DDC movement in the dermis. 
(a and b) Extended focus snapshots of  
the dermis in the steady-state (a) or 24 h 
after injecting CFA s.c. (b). Tracks show the 
motion of selected DDCs through 45 min 
(arrowheads indicate the endpoints of 
tracked cells). (c and d) Charts representing 
the three-dimensional paths, normalized to 
their starting coordinates, taken by the cells 
tracked above. (e and f) Crawling velocities 
(e) and arrest coefficients (f). Shown is the 
percentage of time in which cells were  
immobile (slower than 2 µm/min). Data 
points represent individual cells (n of steady 
state = 535, n of CFA-treated = 305) and were 
pooled from six mice and 15 movies for 
each condition. Red bars denote the mean. 
Inflammation increased velocities and  
reduced arrest. *, P < 0.0001 for both.JEM Vol. 208, No. 10 
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To verify that immobilized CCL21 can trigger DC adhe-
sion, rather than chemokinesis, we studied the behavior of 
WT and CCR7/ BMDCs in a flow chamber coated with 
CCL21. Unlike CCR7/ cells, WT DCs settled the surface, 
spread, and exhibited tight adhesion under flow conditions. 
Adhesion likely depended on inside-out activation of -2   
integrins because it was abolished in the absence of Mg+2 ions 
(unpublished data).
To establish whether CCL21 injected together with DCs 
would reduce their migration into the LNs by chemotacti-
cally directing them away from lymphatics, we co-injected 
BMDCs with 2.5 µg CCL21. The migration of DCs did not 
Figure 3.  CCR7 plays a dual role in 
DCs mobilization, promoting chemo-
taxis and docking to lymphatics. After s.
c. injection of LPS-activated CFSE-stained 
BMDCs to the footpad, WT DCs (a–c) 
moved linearly toward an initial lymphatic, 
compatible with chemotaxis. DCs that 
crossed the endothelium clustered in the 
proximal sections of initial lymphatics, 
either in blind ends (c, left rectangle) or in 
adjacent sections (c, right rectangle). (d) 
Within 24 h, WT cells have efficiently en-
tered lymphatics. In contrast, CCR7/ cells 
(e) kept crawling in the interstitium by-
passing the lymphatic vessels they en-
countered (four representative cells 
tracked), suggesting that CCR7 promotes 
DC adhesion to lymphatics. This pattern 
was also apparent (f) when both WT and 
CCR7/ DCs were co-injected. CCR7/ 
DCs crawled as fast as WT DCs in the der-
mis (P = 0.29; g) but were less persistent  
(P = 0.006; h), implying that CCR7 ligation 
is not essential for DC chemokinesis but 
participates in their chemotaxis. Persis-
tence index was calculated by dividing the 
cell displacement by path length. Data 
points represent individual cells and were 
pooled from three mice for each condition. 
Red bars denote the mean. *, P = 0.006.  
(i) When BMDCs were co-injected with CCL21, 
their migration to the popliteal LN was not 
affected, indicating that misplaced chemo-
kine did not misguide DCs and prevent 
random migration and docking on endo-
thelial CCL21. Data indicate the percentage 
of injected DCs out of resident LN CD11c+ 
cells. Error bars denote SEM.
change significantly (Fig. 3 i) com-
pared with saline-injected footpads. 
Collectively,  these  results  suggest 
that CCR7 ligands play a dual role, 
first in chemotaxis, and then, more 
critically, in DC docking to the lym-
phatic endothelium.
CCL21 shows a unique punctate expression pattern on LECs
The finding that CCR7-dependent docking was crucial for 
DC mobilization into lymphatics prompted us to investigate 
whether  DCs  in  the  dermis  contact  the  CCR7  ligand 
CCL21 on the initial lymphatics themselves. We used con-
focal  microscopy  to  examine  whole-mount  skin  samples 
from the footpad and ear either at steady state or after in-
flammation induced by contact hypersensitivity (CHS) or 
CFA. Staining for LYVE-1 and CCL21 revealed that CCL21 
was not uniformly distributed along the LECs but concen-
trated on discrete regions of the cells (Fig. 4 a). A similar 
pattern was visible in skin samples from footpads (Fig. 4 a) 2146 DC migration toward and through lymphatics | Tal et al.
CCL21 ligation may help DCs traverse the 
basement membrane and interact with LECs
The recent observation that before entering ini-
tial lymphatics DCs traverse the basement mem-
brane through preformed portals (Pflicke and 
Sixt, 2009) raises the possibility that CCL21 is 
associated with these sites. We visualized the 
portals in the basement membrane by staining 
whole mounts of ear skin for collagen IV. The 
basement membrane of initial lymphatics was 
indeed perforated and, interestingly, we found 
that CCL21+ puncta were associated with these 
perforations in >95% of the cases (Fig. 5, a and b). 
Moreover, treating skin samples with collage-
nase  type  IV,  in  the  presence  of  calcium,   
effectively dissociated the majority of CCL21 
from initial lymphatics, supporting the associa-
tion of CCL21 with collagen IV at the base-
ment membrane of the vessels (Fig. 5, c and d).
We  next  examined  the  interaction  of   
endogenous DDCs identified by MHC class II 
(Fig. 5, e–h) or EYFP expression (Fig. 5, i–l) 
with CCL21+ regions of initial lymphatics in 
the ear skin. 24 h after induction of inflammation, endogenous 
DCs preferentially clustered around the proximal portion of 
the vessel. More to the point, some DCs that approached the 
CCL21+ lymphatics extended protrusions toward them and 
contacted the chemokine puncta (Fig. 5, e–l; and Video 8), 
likely allowing them to attach to the vessels. Altogether, these 
results further support a novel role of CCR7-CCL21 signaling 
in mediating docking of DCs to initial lymphatics, which is a 
requirement for subsequent transmigration.
DCs transmigrate through the endothelium of initial 
lymphatics and accumulate in selected sections
After docking to the abluminal surface of lymphatics, DCs 
(either endogenous or transferred and imaged as described in 
the previous section) typically did not crawl along the ablu-
minal surface of the endothelium before starting to trans-
migrate (Fig. 3 a and Video 5). Within 30 min of docking, DCs 
succeeded to penetrate the lumen, where they were released 
(Fig. 6 a and Video 9).
and ears (Fig. 4 b). The punctuate distribution of CCL21   
on  initial  lymphatics  was  particularly  conspicuous  after 
three-dimensional isosurface rendering of confocal image 
stacks (Fig. 4 c).
LECs in initial lymphatics are joined by button junc-
tions that contain VE-cadherin and are interspaced by 
flaps that allow cellular transmigration (Pflicke and Sixt, 
2009). Triple staining of initial lymphatics for VE-cadherin, 
CCL21, and LYVE-1 (Fig. 4, d and e) showed that CCL21 
did not colocalize with VE-cadherin in buttons. Instead, 
CCL21 concentrations lied close to, but not within, the 
LYVE-1–positive flaps. This location suggests that CCL21 
promotes the docking of DCs to the endothelium rather 
than  their  subsequent  transmigration  through  the  flaps.   
Interestingly, compared with the steady state (Fig. 4 f), skin 
inflammation, either through CHS (Fig. 4 g) or CFA (Fig. 4 h), 
did not enhance CCL21 puncta nor disrupted their pattern, 
although it did increase the flow of lymph to the draining 
LN (Fig. S2).
Figure 4.  CCL21 depositions are concentrated in 
specific regions of LECs. Whole-mount confocal  
images of the skin of the footpad (a) or ear (b) stained for 
LYVE-1 and CCL21 showed a punctate expression of 
CCL21 on initial lymphatics (blue dots). (c) This pattern 
was even more obvious after isosurface rendering.  
(d and e) Triple staining for VE-cadherin, LYVE-1, and 
CCL21 shows alternate arrangement of VE-cadherin at 
button junctions and LYVE-1 at loose flaps. CCL21 
puncta are located in the junction-free areas of the 
LECs. (f–h) Compared with the steady-state, inflamma-
tion, either through CHS (g) or CFA (h), did not affect 
the pattern of CCL21 puncta or increase the CCL21 
signal after 24 h.JEM Vol. 208, No. 10 
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lymphatics. Instead, we observed that they ac-
tively crawled inside the lymphatic lumen (Fig. 7 a 
and Video 11), advancing at a slow mean veloc-
ity of 7.75 µm/min. The flattened cross section 
of initial lymphatics permitted DCs to maintain 
close contact with both the bottom and top luminal 
surfaces of these vessels and crawl by extending   
filopodia at their leading edges and exhibiting 
clear uropods at their trailing edges (Fig. 7 b). 
Similar behavior was exhibited by endogenous 
CD11c-EYFP+  DDCs  (Video  4).  Cells  occa-
sionally  reversed  their  polarization  (Video  11) 
and traveled back and forth in the lymphatics, or 
even lodged into the blind end. This irregular 
motion exhibited itself in a relatively low mean 
persistence index of 0.36.
The nondirectional movement of DCs inside the lym-
phatics seemed counterintuitive, as such random motility 
would delay their arrival to the LN. We suspected that 
anesthesia had decreased the flow of lymph in the initial 
lymphatics  and  compromised  DC  migration.  Various   
anesthetics have long been known to reduce lymph flow by 
abolishing voluntary muscle movements, reducing muscle 
tone, and decreasing lymphangion contraction (Schmid-
Schönbein, 1990).
To test this possibility we s.c. injected 4 × 106 GFP+ DCs 
to the footpads of awake or continuously anaesthetized mice 
and harvested their popliteal LNs 10 h later. Anesthesia re-
duced the percentage of newly migrating DCs fivefold (P < 
0.001), lending credibility to our hypothesis (Fig. 7 c).
DCs tended to cross the endothelium at preferred sec-
tions of the initial lymphatics and clustered before releasing 
(Fig. 3 c and Video 5). Clustering occurred at the blind ends 
of lymphatics, or immediately downstream, but not further 
along the vessels. On several occasions we observed two DCs 
successively  transmigrating  through  the  exact  same  points 
(Fig. 6 b and Video 10), likely representing the aforemen-
tioned portals (Pflicke and Sixt, 2009).
The mode of DC propagation in initial lymphatics  
is active crawling
DCs that have entered initial lymphatics need to migrate di-
rectionally to reach the draining LN. We expected the lymph 
flow to sweep the cells downstream as soon as they enter the 
Figure 5.  CCL21 immobilization on the basement 
membrane of initial lymphatics may facilitate DC adhe-
sion at CCL21-rich sites and passage through dedicated 
portals. (a) Collagen IV staining in whole-mount prepara-
tions of the ear skin shows perforations within the basement 
membrane of initial lymphatics (arrows in boxed region).  
(b) CCL21 staining reveals that several, but not all, of these 
perforations (arrows) are associated with CCL21 puncta.  
(c) Treatment of skin cross sections with type IV collagenase 
digested the basal membrane of initial lymphatics, markedly 
reducing collagen on lymphatics. Membrane-bound 
CCL21was dissociated, leaving behind small perinuclear 
depositions (arrows). (d) In the presence of the calcium che-
lator EDTA, collagenase IV treatment did not disrupt collagen 
(left) and CCL21 (right). (e–h) 24 h after contact sensitiza-
tion, skin whole mounts were triple-stained for LYVE-1, 
CCL21, and MHC-II. MHC-II+ DCs accumulated outside initial 
lymphatics (e). (f) Enlargement of the boxed region in  
e shows in three dimensions a DC which extended protru-
sions toward the initial lymphatic vessel and contacted two 
CCL21-rich puncta. Two other examples of DCs contacting 
CCL21 are shown (g and h). (i–l) Similar results were  
obtained when the skin of CD11c-EYFP mice was analyzed. 
Collectively, these findings suggest that CCL21 is secreted 
from intracellular stores inside LECs and is immobilized on 
the basal membrane (often near preformed portals), to pro-
mote DC adhesion and site-specific transmigration.2148 DC migration toward and through lymphatics | Tal et al.
DISCUSSION
We have followed the multistep journey of 
DCs from the inflamed skin to the draining 
LN. In the intact dermis, most DDCs ad-
hered  to  blood  vessels  and  showed  little 
movement.  After  sensing  an  inflammatory 
signal, DCs accelerated 2.5-fold and patrolled 
the dermis. Ligation of CCR7 on DCs al-
lowed them to dock to punctate CCL21 de-
positions on the abluminal surface of initial 
lymphatics and enter them, most likely through 
dedicated portals. In contrast, CCR7-deficient DCs crawled 
as rapidly but less persistently in the dermis, contacting lym-
phatics but failing to dock and transmigrate. Once inside 
initial lymphatics, DCs used their lamellipodia to interact 
with the endothelium, and, guided by the direction of lymph 
flow,  polarized  and  actively  crawled  toward  the  draining 
LN. After reaching collecting lymphatics, DCs started drift-
ing freely in the lymph flow.
Two recent studies described how CD11c-EYFP+ DDCs 
in the ear respond to inflammatory agents (Ng et al., 2008; 
Sen et al., 2010). The DDCs recorded by Sen et al. (2010) 
were initially sessile and accelerated in response to a skin irri-
tant or to adjuvants. In contrast, Ng et al. (2008) found that 
DDCs crawled constantly in the steady state and stopped in 
response to systemic LPS administration or to local Leishma-
nia infection. Here, we studied DDC dynamics in the foot-
pad  skin  and  found  that  CFA-mediated  inflammation 
mobilized the normally sessile DDCs. The disagreement be-
tween our data and those of Ng et al. (2008) may be ex-
plained by the different skin areas examined (footpad and ear, 
respectively) or the depth at which cells were recorded; the 
present study examined DDCs in the deep dermis, whereas 
the ear model investigated DDCs in the upper dermis. The 
DDCs in our footpad preparation responded to inflammation 
like those studied by Sen et al. (2010) in the ear. But for un-
known reasons this group could not identify DDCs in the 
footpad, so the data cannot be directly compared.
The physiological importance of chemotaxis toward solu-
ble chemokines is a long-standing question (Proudfoot et al., 
2003) that we address here in the context of lymphatic intra-
vasation  under  inflammation.  CCR7  ligands  were  initially   
envisioned as soluble chemoattractants released to promote DC 
motility and attract them to lymphatics (Saeki et al., 1999). 
Mounting in vitro evidence, however, suggests that CCL21 
Next we studied how lymph flow affects the motility of 
DCs inside lymphatics. Because it has been shown that ele-
vated interstitial flow increases lymph flow and DC migra-
tion to LNs (Miteva et al., 2010), we manipulated lymph 
flow by artificially increasing the pressure of the interstitial 
fluid. After locating transferred DCs inside initial lymphat-
ics, we s.c. injected 5–10 µl of PBS containing a fluorescent 
tracer (QD655) and followed the motion of the DCs (Fig. 7 d 
and  Video  12).  The  fluid  could  be  observed  diffusing 
through the dermal interstitium and concentrating in initial 
lymphatics. DCs responded to the flow by propagating to-
ward the LN. Although their crawling velocity remained 
constant at 8 µm/min, their persistence index increased 
from 0.375 to 0.65 as they started moving linearly along 
the vessel. Cell morphology and speed indicated that DCs 
remained in close contact with the endothelium through-
out this process. When mice were anesthetized with iso-
flurane, which is believed to interfere less with lymph flow 
(Video 13), cells showed a propensity to crawl directionally 
toward LNs, but still crawled in close contact with the 
lymphatic endothelium.
DCs flow passively in collecting lymphatics
As expected, in the faster-flowing collecting lymphatics, 
DCs  drifted  passively  rather  than  crawling  actively.  We 
could observe cells drifting at high speeds in the large col-
lecting and afferent lymphatics leading to the popliteal LN 
(Fig. S3 a). Measurements revealed speeds of 1,200 µm/min, 
which is 200-fold faster than the maximal crawling speed 
recorded  in  the  initial  lymphatics.  In  accordance  with   
previous results (Lindquist et al., 2004), once inside the 
draining LN the transferred DCs dispersed in the subcap-
sular sinus (Fig. S3 b and Video 14) before migrating into the 
T cell zone.
Figure 6.  DCs trans-migrate through the endo-
thelium in selected lymphatic sections. The footpad 
was injected with BMDCs s.c. with 24 h before imaging. 
(a) Sequential images (timed 0–40 min) demonstrate 
the typical dynamics of DC transmigration; within  
20 min, a DC that adhered to abluminal surface of a lym-
phatic vessel trans-migrated into the lymphatic lumen 
and started crawling. (b) Two DCs cross through the 
same spot on the endothelium, presumably represent-
ing a preformed portal (Pflicke and Sixt, 2009).JEM Vol. 208, No. 10 
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CCR8  (Qu  et  al.,  2004)  and  CXCR4   
(Kabashima  et  al.,  2007)  which  partially 
overlap with CCR7 signaling.
After DCs dock to lymphatics, micro-
anatomical  structures  likely  channel  their 
entry into the vessels. In two studies, the 
group led by M. Sixt recently described the 
entry of DCs into lymphatics in an explanted preparation of 
the  ear  skin  (Lämmermann  et  al.,  2008;  Pflicke  and  Sixt, 
2009). They showed that DCs cross the basement membrane 
through preformed portals and then, as suggested previously 
(Baluk et al., 2007), squeeze through flaps between the button 
junctions of initial lymphatics. The present study is the first to 
demonstrate  intravitally  that  several  DCs  can  successively   
enter through the same portal. It also pinpoints the distribution 
of CCL21 on initial lymphatics, where chemokine puncta 
decorate the basal membrane, often next to portals. We pro-
pose that CCL21 secreted from the basal aspect of LECs is 
trapped by collagen type IV in the basement membrane acting 
as a substrate for DC docking. Additional components may 
also participate in this process. These include glycosamino-
glycans (Hirose et al., 2001; Patel et al., 2001) or podoplanin 
(Kerjaschki et al., 2004), a glycoprotein expressed selectively 
on the lymphatic endothelium (Mäkinen et al., 2007).
Rather than acting as an adhesion molecule alone, we 
suggest that immobilized CCL21 promotes DC adhesion and 
transmigration by triggering the activation of integrins. The 
fact  that  inflammation  up-regulates  the  integrin  ligands 
ICAM-1 and VCAM-1 on lymphatic vessels (Johnson et al., 
2006) and that CCL21 promotes DC adhesion to ICAM 
(Schumann et al., 2010) suggests as much. Our in vitro data, 
has an equally important role as an immobilized ligand. In this 
form, it primarily promotes leukocyte arrest rather than mi-
gration; it triggers T cell arrest on ICAM-1 under flow condi-
tions (Campbell et al., 1998), mediates T cell tethering to DCs 
(Friedman et al., 2006), and promotes DC adhesion and spread 
on  integrin  ligands  (Woolf  et  al.,  2007;  Schumann  et  al., 
2010). The latter group also proposed a synthesis of these two 
functions by showing that the immobilized CCL21 can be 
cleaved by DCs and released to attract more DCs to the T cell 
zones in LN sections. Here, we present the first in vivo evi-
dence for the crucial role of immobilized CCL21. We sug-
gest, based on the migration patterns of CCR7/ DCs, that 
immobilized CCR7 ligands affix DCs to the basal membrane 
lining the lymphatic endothelium and activate their program 
for trans-endothelial migration. We support the specific role 
of CCL21 by ex vivo immunohistology. Conceivably, acti-
vated DCs that migrate randomly in the dermis encounter 
the  immobilized  chemokine  on  the  basement  membrane, 
dock to it, and generate soluble CCL21 to chemotactically at-
tract more DCs. A potential difficulty is that CCL21 would 
have to diffuse against the flow of interstitial fluid toward 
lymphatics (Swartz et al., 2008). The small minority of 
CCR7/ DCs that managed to enter lymphatics by bypassing 
this checkpoint may have used chemokine receptors such as 
Figure 7.  DCs actively crawl inside initial lym-
phatics using lymph flow as a directional cue. 
(a) Sequential images of BMDC propagation inside 
initial lymphatics. Circled is a DC crawling inside 
the lymphatic lumen. (b) At a higher magnification 
a DC is seen crawling using lamellipodia at the 
leading edge and a well defined uropod at the trail-
ing edge. Sequences are representative of at least 
13 independent experiments. (c) Under general 
anesthesia, which is known to reduce lymph flow, 
the percentage of immigrant GFP+ BMDCs from the 
footpad skin, as recorded in the popliteal LN 10 h 
after transfer, drops fivefold (P < 0.001). Data rep-
resent three independent experiments. Red bars 
denote the mean. *, P < 0.001. (d–f) In the presence 
of lymph flow, DCs move directionally in the lym-
phatics. Mice were injected s.c. with 5 µl of fluores-
cently stained saline (red). As fluid diffused through 
the interstitium and concentrated in lymphatics,  
DCs switched from random motility inside lym-
phatics (d) to directional crawling toward the LN (e).  
Tracks show several DCs following the same route 
down the lymphatic vessel (f). Under these condi-
tions DCs crawled along the lymphatic vessel at a 
mean speed of 9.06 µm/min and a persistence  
index of 0.65.2150 DC migration toward and through lymphatics | Tal et al.
the faster flow and reach the draining LN rapidly. Pinpointing 
the molecular cascades underlying this sequence of events now 
becomes an interesting course to follow.
MATERIALS AND METHODS
Transgenic mice. Animals were maintained in a specific pathogen-free   
facility under conditions approved by the institutional animal care and use 
committee of the Weizmann Institute of Science and the National Univer-
sity of Singapore. Transgenic mice expressing Venus EYFP under the control 
of the CD11c promoter specifically tagging the DC population were the gift 
of M. Nussenzweig (The Rockefeller University, New York, NY) and have 
been previously described (Lindquist et al., 2004). In brief, these mice express 
high levels of EYFP in all DC populations except plasmacytoid DCs. Expres-
sion in other cell populations is too dim to visualize. In the skin, the EYFPhi 
population consists exclusively of LCs and DDCs (Ng et al., 2008).
The following mouse strains were used in BMDC transfer experiments: 
(a) BALB/c mice as donors and hosts, (b) CCR7/ mice back-crossed to 
C57bl/6 (the gift of S. Lira, Mount Sinai Medical Center, New York, NY) 
as  donors,  (c)  ubiquitin-EGFP  mice  (C57BL/6-Tg(UBC-GFP)30Scha/J; 
The Jackson Laboratory) as donors, and (d) albino tyrosinase-deficient 
C57BL/6 mice (B6(Cg)-Tyrc-2J/J; The Jackson Laboratory) as hosts.
Induction of inflammation. Footpad inflammation was induced by s.c. 
injection of 50 µl CFA (Sigma-Aldrich). 24 h after induction of inflammation 
the footpad was imaged to track the interaction of DDCs with lymphatics.
For whole-mount staining, CHS was achieved by epicutaneous appli-
cation of a 1:1 mixture of acetone and dibutyl phthalate to the ear skin as 
described previously (Angeli et al., 2006). Ears were collected for immuno-
histochemical analysis 24 h after sensitization.
Generation of BMDCs. BMDCs were generated based on a modified es-
tablished protocol (Lutz et al., 1999). In brief, 4 × 106 cells were cultivated 
for 13 d in RPMI, supplemented with 10% GM-CSF–conditioned GM-B16 
supernatant, which is equivalent to 200 U/ml recombinant mouse GM-CSF 
(Inaba et al., 1992). One volume of fresh media was added on day 3, and on 
days 6 and 8 one volume was replaced by fresh media. On day 10, floating 
cells were transferred to new dishes. Cells were harvested on days 9–13. 
Analysis of harvested cells revealed that 85–95% expressed CD11c, with   
40–60% positive for MHC-II.
Preparation of mice for imaging. Before imaging, mice were anesthe-
tized by i.p injection of 100 mg/kg ketamine + 15 mg/kg xylazine + 2.5 
mg/kg acepromazine. Anesthesia was supplemented hourly with half this 
dose. Mice were placed on a warmed plate and kept at a core temperature of 
37°C. The hind paw was placed on a thermally conductive stage (T putty; 
Laird Technologies) and covered with a glass-bottom imaging chamber.
Live two-photon microscopy of DCs in the skin. We used a micro-
scope (Ultima Multiphoton; Prairie Technologies) incorporating a pulsed   
laser (Mai Tai Ti-sapphire; Newport Corp.). The laser was tuned to 850 nm 
to simultaneously excite EYFP and Texas Red, 800 nm to simultaneously ex-
cite CFSE and Texas Red, or 880 nm to excite EYFP and Hilyte Fluor 594. 
A water-immersed 20× (NA 0.95) or 40× (NA 0.8) objective (Olympus) was 
used. To create a typical time-lapse sequence, a 50-µm-thick section of the 
dermis containing lymphatic vessels was scanned at 4-µm Z-steps every 30 s.
DC and lymphatic vessel imaging. DCs were labeled with fluorescent 
dyes. Cells were either incubated in 5% FCS PBS for 5 min with 5 µM 
CFSE (AnaSpec) at room temperature or with CellTracker blue (Invitrogen) 
in RPMI for 30 min in 37°. Alternatively, GFP+ cells were used.
To image initial lymphatics without interfering with DC migration 
(Gale et al., 2007), we visualized LYVE1. Rat anti–mouse LYVE-1 (clone # 
223322; R&D Systems) was covalently conjugated to Texas red or to HiLyte 
Fluor 594 using labeling kits (AnaSpec). A volume of 50 µl PBS containing 
as well as recent in vitro work using human cells (Johnson 
and Jackson, 2010), support this scenario directly.
In clinical trials, usually only 5% of injected monocyte-
derived DCs reach the draining LN (De Vries et al., 2003). In 
stark contrast, we typically observe that 95% of LPS-activated 
BMDCs have entered the lymphatic capillaries 18 h after in-
jection. If one is willing to accept that this finding represents 
clinical reality, then the rate-limiting step for DC migration 
from the skin cannot be recruitment into the lymphatics;   
instead, it might be dispersion within the dermis or crawling 
in initial lymphatics.
Conducted in intact animals in the presence of lymph 
flow, our study shows directional cellular motility inside lym-
phatics. This is the first study to reveal how leukocytes, DCs 
in this case, propagate in initial lymphatics. We show that lym-
phatic propagation is hardly the long-imagined passive pro-
cess produced by hydrodynamic forces. Instead, it requires 
elaborate crawling guided by a weak lymph current. The sim-
plest interpretation would be that intralymphatic DC migra-
tion is essentially random and they are physically pushed 
downstream by the shear flow of the lymph. Nonetheless, 
DCs maintained their typical polarized crawling morphology, 
moved relatively slowly, and departed from their original clus-
ters in a noncoordinated fashion, suggesting directional crawl-
ing. It remains unclear how DCs polarize along the lymph 
flow. Possible mechanisms include integrin-based mechanical 
sensing of shear forces (Alon and Dustin, 2007) and chemo-
taxis down an intraluminal gradient of chemokines, perhaps 
produced by the DCs themselves (Shields et al., 2007; Swartz 
et al., 2008).
Further complexity is added by a possible change in the 
profile of CCR7-ligands somewhere along lymphatics, from 
predominantly CCL21-leu on initial lymphatics to CCL21-
ser alone in LN sinuses (Vassileva et al., 1999; Randolph   
et al., 2005). This transition may manifest itself in the pheno-
type of plt mice, in which CCL21-leu is expressed in periph-
eral lymphatics but DCs still fail to efficiently migrate into 
LNs (Gunn et al., 1999; Randolph et al., 2005). We are now 
using such mice to determine whether lymphatic vessels need 
to express CCL21 on the luminal surface of their entire 
length to allow DC migration.
Active DC crawling would have to engage adhesion mol-
ecules (such as integrins and their ligands) on both DC and 
endothelial cell. Many such molecules are up-regulated by in-
flammatory conditions (Johnson et al., 2006). This additional 
new step in the course of DC mobilization may thus partici-
pate in controlling the rate of DC recruitment to the LN.
Overall, our findings outline a reverse course of events to 
that observed as leukocytes extravasate into tissues. DCs start by 
migrating semi-randomly in the dermis, relying on immobi-
lized CCL21 for trans-endothelial migration. In initial lymphat-
ics the lymph current may not be powerful enough to physically 
push the DCs. The cells overcome this limitation by sensing the 
direction of flow, polarizing, and actively crawling downstream. 
In collecting lymphatics (perhaps after a rolling phase that we 
have not captured yet), DCs switch to passive drifting to exploit JEM Vol. 208, No. 10 
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Video 3 follows DC motility in injured skin. Video 4 follows CD11c-EYFP+ 
DDCs inside lymphatics. Video 5 demonstrates chemotaxis of BMDCs toward 
lymphatics and clustering inside them. Video 6 exhibits a three-dimensional 
reconstruction of a DC contacting CCL21 puncta. Video 7 compares the   
migration of WT and CCR7/ DCs in the dermis, pinpointing defects in DC 
mobilization into lymphatic vessels.  Video 8 compares the migration patterns of 
co-injected WT and CCR7/ DCs. Video 9 shows trans-endothelial migra-
tion of a BMDC into lymphatics.  Video 10 captures DC entry through possible   
preformed portals. Video 11 shows intralymphatic crawling dynamics. Video 12 
shows the effects of increased lymph flow on intralymphatic DC crawling. 
Video 13 shows intralymphatic crawling dynamics under isoflurane anesthesia, 
Video 14 is a three-dimensional reconstruction of the dispersion of BMDCs in 
the draining LN. Online supplemental material is available at http://www.jem 
.org/cgi/content/full/jem.20102392/DC1.
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2.5–3.5 × 106 DCs, 50 ng LPS (Sigma-Aldrich), and 200 µg anti-LYVE1 
was s.c. injected into the hind footpad.
To visualize collecting lymphatics, 30 µl Evans blue (1%; Sigma-Aldrich) 
was injected s.c. to the hind paw. Lymphatics were followed to the upper shin, 
and the skin was incised 3 mm below the popliteal LN for visualization.
In vivo DC migration assay. To quantify the efficiency of DC migration 
to the popliteal LN, we s.c. injected 4 × 106 EGFP+ BMDCs to the hind 
footpad of either awake or continuously anaesthetized mice. LNs were har-
vested 10 h later and incubated for 45 min at 37°C with 1 mg/ml collagenase D 
(Roche) diluted in PBS and supplemented with CaCl and MgCl (Sigma- 
Aldrich). LN cells were then dissociated and analyzed by standard flow cytom-
etry for CD11c (clone N418; BioLegend) and EGFP expression.
Immunostaining. 10-µm-thick cryosections from the skin were prepared 
as described previously (Lim et al., 2009). For immunohistochemistry, the 
primary antibodies used included LYVE-1 (rabbit polyclonal, Abcam; or rat 
clone 223322, R&D systems) and CCL21 (goat polyclonal; R&D Systems). 
Cy2-conjugated anti–rabbit and Cy3-conjugated anti–goat (Jackson Immuno-
Research Laboratories) were used for detection. Sections were counter-
stained with DAPI to visualize cell nuclei, and mounted for analysis.
Whole-mount immunohistochemical analysis of ear and footpad skin 
was performed as described previously (Lim et al., 2009). Mice were per-
fused with 2% paraformaldehyde, and the tissue was dissected and further 
fixed  in  2%  paraformaldehyde  overnight  at  4°C.  Samples  were  washed, 
blocked with 0.5% bovine serum albumin and 0.3% Trition X-100 in PBS, 
and incubated with primary antibodies overnight at 4°C. The antibodies 
used were directed against LYVE-1 and CCL21 (as in the previous para-
graph), VE-cadherin (rat clone 11D4.1; BD), Collagen IV (rabbit polyclonal; 
Cosmobio), and MHCII (rat clone M5/114.15.2; eBioscience). Secondary 
antibodies conjugated to Cy2, Cy3, and Dy649 (Jackson ImmunoResearch 
Laboratories) were used for detection.
Specimens were viewed with a widefield (Axio Imager.Z1; AxioCam 
HRM camera; Carl Zeiss) or confocal microscope (TCS SP5; Leica) using 
LAS AF confocal software (version 1.8.2; Leica). Isosurface rendering and 
confocal z-stacks were processed using Imaris (Bitplane).
Macroscopic lymph flow assessment. To assess the volume of lymph 
reaching the popliteal LN over 20 min, mice were treated in one footpad 
with CFA, as described in Induction of inflammation. 24 h later, mice were 
anesthetized with 1.5% isoflurane and their thighs were shaved for imaging 
using Xenogen IVIS S100. 40 µl of 70-kD (6.25 mg/ml) Dextran-FITC was 
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yielded significant results.
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